tbuckley/cabot-search huggingface dataset:
Lung cancer risk factors in a minority population
Authors: Carol J. Etzel, Mei Liu, Margaret Spitz
Journal: Cancer Research (2006)

4558   Introduction: Cancer is one of the leading causes of morbidity and death among minorities, but there is still limited knowledge regarding lung cancer (LC) risk in these populations. The goal of this project was to identify risk factors associated with LC in Mexican-Americans (MA) and African-Americans (AA). Methods: The 422 LC cases of AA descent and 189 cases of MA descent were patients referred to UT M.D. Anderson Cancer Center, Houston. The 759 controls were recruited from health clinics in the Houston area and matched to the cases on age (±5 yrs), sex and ethnicity. All data were derived from personal interviews. Results and Conclusions: Roughly 10% of all LC cases are never smokers; however, we observed a higher proportion (36.5%) of never smokers in our MA women cases. AA women who smoked more than 20 cigarettes/day had a 15-fold increased risk of LC compared to AA women who smoked less, while risks for MA and AA men were moderate. Although minorities tend to smoke more menthol cigarettes than Whites, we observed no increased risk of LC among MAs or AAs who smoked menthol cigarettes compared to non-menthol minority smokers. Cessation of smoking greater than 10 years was associated with decreased risk of LC for MA men and all AAs [OR range=0.25-0.42]; however, we observed no such decrease among MA women. AAs exposed to asbestos (OR=1.59, 95%CI=1.16-2.17) were at increased risk for LC; similar to our previous reports for Whites. MAs with pesticide exposure were at increased risk for LC (OR=3.97, 95% CI=2.08-7.57). Prior diagnosis of emphysema was associated with a 6 to 8-fold increased risk for LC [MA OR=8.09, 95%CI=2.32-28.32; AA OR=6.58, 95%CI=3.08-14.04]; substantially higher than what we have previously reported for Whites. We further observed a protective effect of hay fever among minorities similar to our previous findings for Whites (OR range=0.42-0.64). MA and AA women who consumed at least 1.7 FDA pyramid servings/day of fruit were at lower risk for LC (OR range=0.27-0.57); while men who consumed vegetables containing Isothiocyanate were at decreased risk for LC [MA (OR=0.51, 95%CI=0.32-0.82); AA (OR=0.66, 95%CI=0.48-0.97)]. Similar to Whites, higher intake of food folate was associated with a 42% decreased risk of LC among AAs (OR=0.58, 95%CI=0.34-0.99). Phytoestrogens are associated with a decrease in risk of LC in Whites; however, we did not observe a significant association in this minority population. Among the LC cases, there was no difference in survival (P=0.54) between the MAs and AAs; however, within each race group, women had better survival [MA (adj HR= 0.62, P=0.03); AA (adj HR=0.73, P-0.01)] than the men. This investigation demonstrates that minorities may share common LC risk factors with Whites and each other; however, level of LC risk may differ depending on type and level of exposure. Further research is needed to elucidate risk factors for LC in minorities. This project was supported by NCI grants CA55769, CA70907 & CA093592 and FAMRI, DAMD17-02-1-07-06.
BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells
Authors: B Sun, W Fiskus, Y Qian, K Rajapakshe, K Raina, K G Coleman, A P Crew, A Shen, D T Saenz, C P Mill, A J Nowak, N Jain, L Zhang, M Wang, J D Khoury, C Coarfa, C M Crews, K N Bhalla
Journal: Leukemia (2017)
Arterial Stiffening With Exercise in Patients With Heart Failure and Preserved Ejection Fraction
Authors: Yogesh N.V. Reddy, Mads J. Andersen, Masaru Obokata, Katlyn E. Koepp, Garvan C. Kane, Vojtech Melenovsky, Thomas P. Olson, Barry A. Borlaug
Journal: Journal of the American College of Cardiology (2017)
Association Between Pregnancy and Perinatal Outcomes Among Women With Epilepsy
Authors: Neda Razaz, Torbjörn Tomson, Anna-Karin Wikström, Sven Cnattingius
Journal: JAMA Neurology (2017)

To date, few attempts have been made to examine associations between exposure to maternal epilepsy with or without antiepileptic drug (AED) therapy and pregnancy and perinatal outcomes.To investigate associations between epilepsy in pregnancy and risks of pregnancy and perinatal outcomes as well as whether use of AEDs influenced risks.A population-based cohort study was conducted on all singleton births at 22 or more completed gestational weeks in Sweden from 1997 through 2011; of these, 1 424 279 were included in the sample. Information on AED exposure was available in the subset of offspring from July 1, 2005, to December 31, 2011. Data analysis was performed from October 1, 2016, to February 15, 2017.Pregnancy, delivery, and perinatal outcomes. Multivariable Poisson log-linear regression was used to estimate adjusted risk ratios (aRRs) and 95% CIs, after adjusting for maternal age, country of origin, educational level, cohabitation with a partner, height, early pregnancy body mass index, smoking, year of delivery, maternal pregestational diabetes, hypertension, and psychiatric disorders.Of the 1 429 652 births included in the sample, 5373 births were in 3586 women with epilepsy; mean (SD) age at first delivery of the epilepsy cohort was 30.54 (5.18) years. Compared with pregnancies of women without epilepsy, women with epilepsy were at increased risks of adverse pregnancy and delivery outcomes, including preeclampsia (aRR 1.24; 95% CI, 1.07-1.43), infection (aRR, 1.85; 95% CI, 1.43-2.29), placental abruption (aRR, 1.68; 95% CI, 1.18-2.38), induction (aRR, 1.31; 95% CI, 1.21-1.40), elective cesarean section (aRR, 1.58; 95% CI, 1.45-1.71), and emergency cesarean section (aRR, 1.09; 95% CI, 1.00-1.20). Infants of mothers with epilepsy were at increased risks of stillbirth (aRR, 1.55; 95% CI, 1.05-2.30), having both medically indicated (aRR, 1.24; 95% CI, 1.08-1.43) and spontaneous (aRR, 1.34; 95% CI, 1.20-1.53) preterm birth, being small for gestational age at birth (aRR, 1.25; 95% CI, 1.13-1.30), and having neonatal infections (aRR, 1.42; 95% CI, 1.17-1.73), any congenital malformation (aRR, 1.48; 95% CI, 1.35-1.62), major malformations (aRR, 1.61; 95% CI, 1.43-1.81), asphyxia-related complications (aRR, 1.75; 95% CI, 1.26-2.42), Apgar score of 4 to 6 at 5 minutes (aRR, 1.34; 95% CI, 1.03-1.76), Apgar score of 0 to 3 at 5 minutes (aRR, 2.42; 95% CI, 1.62-3.61), neonatal hypoglycemia (aRR, 1.53; 95% CI, 1.34-1.75), and respiratory distress syndrome (aRR, 1.48; 95% CI, 1.30-1.68) compared with infants of unaffected women. In women with epilepsy, using AEDs during pregnancy did not increase the risks of pregnancy and perinatal complications, except for a higher rate of induction of labor (aRR, 1.30; 95% CI, 1.10-1.55).Epilepsy during pregnancy is associated with increased risks of adverse pregnancy and perinatal outcomes. However, AED use during pregnancy is generally not associated with adverse outcomes.
Nitrous oxide CryoBalloon therapy of refractory gastric antral vascular ectasia
Authors: Arvind Trindade, Sumant Inamdar, Divyesh Sejpal
Journal: Endoscopy (2017)

A 69-year-old man with end-stage renal disease on hemodialysis was referred for persistent gastric antral vascular ectasia (GAVE) that required biweekly transfusions. The patient had undergone four endoscopies and treatment with argon plasma coagulation (APC), with no clinical improvement; he was still requiring blood transfusions. Given that the patient was refractory to APC therapy, he was referred for alternative endoscopic therapy.
An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma
Authors: A Lollies, S Hartmann, M Schneider, T Bracht, A L Weiß, J Arnolds, L Klein-Hitpass, B Sitek, M-L Hansmann, R Küppers, M A Weniger
Journal: Leukemia (2017)
Rates and Consequences of False Penicillin Allergies in Australia
Authors: Hannah May Pawlasty, Angus John Thompson, Leanne Chalmers
Journal: JAMA Internal Medicine (2017)

To the Editor The Teachable Moment in a recent issue of JAMA Internal Medicine by Vaisman et al1 graphically illustrates the adverse consequences that can arise for a patient when they are inappropriately labeled as allergic to penicillin.
Comparing efficacy of 1-L peg-asc with prucalopride and 2-L peg-asc for bowel preparation: Prospective randomized controlled trial
Authors: Ji Choi Seong, Sun Kim Eun, Min Lee Jung, Min Lee Jae, Sik Lee Hong, Tae Jeen Yoon, Geeho Min, Soon Choi Hyuk, Woojung Kim, Duck Kim Chang, Jai Chun Hoon, Bora Keum, kyung Yoo In
Journal: Annals of Oncology (2017)
Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma.
Authors: Mrinal M. Gounder, Siraj Mahamed Ali, Victoria Robinson, Mark Bailey, Richard Ferraro, Nirali M Patel, Anita Krishnan, Sherri Z. Millis, Mark Andrew Dickson, Sandra P. D'Angelo, Mary Louise Keohan, Vincent A. Miller, Gary K. Schwartz, Robert G. Maki, William D. Tap
Journal: Journal of Clinical Oncology (2017)

11001 Background: The utility of NGS in management of sarcoma pts remains undefined. Methods: We retrospectively analyzed the NGS profile of patients who were sequenced using a panel of 405 cancer-related genes in DNA and 265 genes rearranged in RNA. Diagnostic and therapeutic implications of mutations (mut) were evaluated through published literature (OncoKb.org, Pubmed). An algorithm was applied to determine germline mut. Following IRB approval, we evaluated the clinical outcomes of pts who underwent NGS at MSKCC. Results: From 2012–2016, 5635 pts worldwide with 56 histologies were tested. Median age of 52 yrs ( &lt; 1-88), 52% females and sarcoma NOS (n = 858) was most frequent. Tumors were sequenced to a mean coverage of 634X; 1165 fusions and &gt; 60,000 mut were found. Mut suspicious for germline defects were seen in 542 pts (9.6%) in known and novel genes ( BRCA, ARID1, FANC). Tumor mutational burden was 2.5/Mb (0–329) and glomus tumors and EHE had the highest and lowest mut, respectively. 16% and 7% of pts had treatment-linked alterations (TLA) known to respond to an FDA approved or study drug, respectively. 42% of pts had TLA eligible for NCI-MATCH, ASCO-TAPUR or other studies. Novel TLA include AKT, ESR1, BRCA, NTRK, PTCH1, SMARCB1 and others. Of the 107 MSKCC pts with clinical data, 60/107 (57%) had at least one TLA, of which 31 (30%) enrolled on a matched trial and 26 pts were ineligible or lacked access to trials. Partial/complete responses were seen with inhibitors to NTRK, IDH1, BRAF, PI3K/mTOR, MDM2, SMARCB1 and others. NGS changed the initial pathology diagnosis and treatments in 5% pts (e.g. LMS to liposarcoma, clear cell to melanoma). Resistance mutations averted futile therapies in 5% pts (e.g. Rb loss and palbociclib in liposarcoma). Conclusions: Our data suggests that NGS has a significant impact in aiding diagnosis and selecting matched therapies in sarcoma. Suspected germline aberrations, while intriguing, needs further validation.
Efficacy of raltitrexed in refractory metastatic colorectal cancer. A retrospective analysis of 84 patients in HUCA (University Hospital Central of Asturias)
Authors: Alfonso Revuelta, Maria Solis, Sara Fernandez-Arrojo, Laura Faez, Clara Iglesias, Jorge del Rio, David Gomex, Paula Fonseca, de Prado Jose Maria Vieitez
Journal: Annals of Oncology (2017)
Abstract 318: Targeting of Tp53inp1 by Mir-221 to Reduce P62-mediated Autophagy is Cardioprotective in Ischemia / Reperfusion Injury
Authors: Peipei Wang, Qiying Chen, Arthur M Richards
Journal: Circulation Research (2015)

Purpose: Tumor protein 53-induced nuclear protein 1 (Tp53inp1) acts as a tumor suppressor by inducing cell death. Tp53inp1 mRNA is a predicted target of miR-221. Whether targeting Tp53inp1 plays a role in miR-221-mediated cardioprotection has not been investigated. We hypothesized that miRNA-221 directly targets Tp53inp1 to reduce ischemia/reperfusion (I/R)-induced autophagy. Method: Myoblast H9c2 cells underwent 16 hours 0.2% O 2 hypoxia followed by 2 hours re-oxygenation (H-R, simulating I/R). H9c2 were transfected with miRNA-221 mimic (25 nmol) and scrambled mimic control (miR-221 and MC). Cell count/viability, WST assay, cell injury-induced LDH release, and GFP-LC3 labeled autophagosome formation were measured. Cells were collected for RT-qPCR and western blot (WB) analyses. pCMV-Myc-Tp53inp1 and pcDNA3.1-Flag-p62 plasmids were cloned and transfected into H9c2 for recovery and immuno-precipitation (IP) studies. The effects of miRNA-221 inhibitor in H9c2 were also assessed. Results: miR-221 significantly reduced H-R injury as indicated by higher cell count/viability and WST activity, and reduced LDH (miR-221 vs. MC p&lt;0.05). qPCR confirmed that (1) miRNA-221 expression was reduced in H-R; (2) RISC-loaded (IP pull-down Ago-2) miRNA-221 increased by ~80 fold and reduced by 95% following mimic and inhibitor transfection respectively; (3) Increased Tp53inp1 following H-R was reversed by miR-221. miR-221 inhibited H-R induced autophagosome formation (GFP-LC3). WB indicated (1) increase of LC3-I/II ratio and p62, indicators of reduced autophagy, and (2) decrease of Tp53inp1 by miR-221. IP pull-down Myc-Tp53inp1 indicated the formation of p62-Tp53inp1 complex. The protective effect of miR-221 was abolished by Tp53inp1 overexpression (pCMV-Myc-Tp53inp1 and miRNA-221 mimic co-transfection). The protective effect was corroborated in neonatal rat ventricular myocytes (NRVM). MiRNA-221 inhibitor induced reverse effects. Conclusion: The cardioprotection of miR-221 entails direct targeting of Tp53inp1 which reducing p62-Tp53inp1 complex formation and inhibiting H-R-induced autophagy.
IGF1-Dependent Synaptic Plasticity of Mitral Cells in Olfactory Memory during Social Learning
Authors: Zhihui Liu, Zijun Chen, Congping Shang, Fei Yan, Yingchao Shi, Jiajing Zhang, Baole Qu, Hailin Han, Yanying Wang, Dapeng Li, Thomas C. Südhof, Peng Cao
Journal: Neuron (2017)
Soundings: “I'm suffering from work related stress, doctor”
Authors: Kevin Barraclough
Journal: BMJ (2000)

My first girlfriend would sometimes ask me, as we wandered along the deep lanes by our Cotswold school, whether I was happy. The question would uniformly plunge me into a state of self questioning doubt. The truth was that, when I paused to examine the question, I was not happy. At least not to the degree that the films shown in the assembly hall on a Saturday night had led me to expect that I should be. But equally I was not unhappy. At least not until she asked me the question.
Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS
Authors: Ryan James Caddell, Braydon Schaible, Zhenjun Ma, Elizabeth Dimaggio, Rebecca Tombleson, Claudio Anasetti, Ernesto Ayala, Brian C. Betts, Mohamed A. Kharfan-Dabaja, Frederick L. Locke, Taiga Nishihori, Joseph A. Pidala, Hugo F. Fernandez, Asmita Mishra
Journal: Blood (2016)
An outbreak of dengue virus (DENV) type 2 Cosmopolitan genotype in Israeli travellers returning from the Seychelles, April 2017
Authors: Yaniv Lustig, Dana Wolf, Ora Halutz, Eli Schwartz
Journal: Eurosurveillance (2017)

Dengue virus infection was diagnosed in six Israeli travellers returning from the Seychelles in April 2017. Phylogenetic analysis identified identical sequences belonging to the Cosmopolitan genotype of dengue virus type 2 in all samples sequenced, thus providing evidence for a probable dengue type 2 outbreak in the Seychelles. This report further demonstrates the role of travellers as sentinels for arboviral infections, especially in countries with limited diagnostic capabilities.
Exclusion of Kaposi Sarcoma From Analysis of Cancer Burden
Authors: Dirk P. Dittmer, Susan E. Krown, Ronald Mitsuyasu
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Association between pretreatment neutrophil to lymphocyte ratio (NLR) and complete pathological response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NACT).
Authors: Kaethe Vivienne Clarke, Eitan Amir, Hal K. Berman, Manjula Maganti, Srikala S. Sridhar
Journal: Journal of Clinical Oncology (2015)

e11588 Association between pretreatment neutrophil to lymphocyte ratio (NLR) and complete pathological response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NC) Background: NLR is a non-invasive indicator of systemic inflammation and may be a negative prognostic marker in several cancers including breast cancer. We aimed to determine if NLR is also a predictive factor for pCR in breast cancer pts undergoing NC and if so to determine the ideal NLR cutoff for predicting pCR. Methods: We retrospectively reviewed 101 charts of pts treated with NC and definitive surgery between Jan 2011 and December 2013. Pretreatment clinical, pathological and laboratory factors were collected. Pts with missing baseline or treatment data were excluded. Statistical significance was reported using Chi-square test or Fisher exact test for categorical variables, and T-test for continuous data. Logistic regression analysis was conducted to identify independent predictors associated with pCR. Results: Of 74 evaluable pts, median age was 52 (32-72), 13 (18%) were triple negative, 26 (35%) were Her2+, and 34 (46%) were ER+/HER2+ and 1/74 (1%) was PR+ only. Median pretreatment NLR was 2.3 (1-15.6); and median platelet count was 242 (153-446). Most pts (94%) were treated with sequential anthracycline and taxane, with trastuzumab given to all Her2+ pts. Overall 16/74 (22%) had a pCR. NLR when analyzed as a continuous and a categorical variable with cutoffs of 2, 2.5, 3 and 3.5 showed no association with pCR. However, a higher baseline platelet count was univariately associated with pCR (p=0.017), as was a negative ER status (p=<0.001) and/or a negative PR status (p=<0.0095). Conclusions: In this study, baseline pretreatment NLR did not predict for pCR, confirming prior reports. However, baseline higher platelet count and negative ER/PR status, emerged as predictive factors for pCR in this patient population and warrants further study.
Outcomes and Costs of Managing Appendicitis at Safety-Net Hospitals
Authors: Roy P. Won, Scott Friedlander, Steven L. Lee
Journal: JAMA Surgery (2017)

Safety-net hospitals serve vulnerable populations with limited resources. Although complex, elective operations performed at safety-net hospitals have been associated with inferior outcomes and higher costs, it is unclear whether a similar association has been seen with common emergency general surgery performed at safety-net hospitals.
Neuroleptics for Delirium: More Research Is Needed
Authors: Ahmed F. Elsayem, Michael J. Fisch
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Abstract 18842: Adherence and Persistence to Apixaban Treatment in Patients With Non Valvular Atrial Fibrillation is High and Similar With Standard of Care Patient Education or With an Additional Educational Program: The Randomized AEGEAN Study
Authors: Gilles Montalescot
Journal: Circulation (2016)

Introduction: Apixaban is a direct oral anticoagulant that has demonstrated superiority over vitamin K antagonists to prevent stroke and systemic embolism in patients with non-valvular atrial fibri...
DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC).
Authors: MinYuen Teo, Kenneth Seier, Irina Ostrovnaya, Ashley Marie Regazzi, Brooke Elizabeth Kania, Meredith Maisie Moran, Catharine Kline Cipolla, Mark J. Bluth, Joshua Chaim, Hikmat Al-Ahmadie, David B. Solit, Samuel Funt, Jedd D. Wolchok, Gopa Iyer, Alexandra Snyder Charen, Dean F. Bajorin, Jonathan E. Rosenberg, Margaret K. Callahan
Journal: Journal of Clinical Oncology (2017)

4509 Background: Somatic DDR alts are associated with increased mutation load (ML) and improved clinical outcomes for platinum-treated mUC (Teo et al, CCR 2017). We examined the relationship between DDR alts and response to PD1/PDL1 blockade. Methods: mUC pts enrolled to phase 2 trials of atezolizumab or nivolumab who had targeted exon sequencing of 410 genes (MSK-IMPACT) were identified. Pts were dichotomized based on presence of alts in a panel of 34 DDR genes. Analyses were performed based on: (1) any DDR alts and (2) deleterious DDR alts (frameshift, splice site, nonsense or Hotspot point mutations). Study endpoint was overall response (OR) per RECIST. ML was defined as total number of nonsynonymous mutations by MSK-IMPACT. Fisher exact, Wilcoxon rank sum, and stratified logistic regression were used. Results: Fifty two pts were identified (atezo: n=18, nivo: n=34). Median age was 67 years (range: 32 – 84) and majority (44) was male. Median platinum-free interval was 10.2 months (range: 0.3 – 150.4). DDR and deleterious DDR were seen in 25 (48.1%) and 14 (26.9%) pts (including 2 MSI and 1 POLE). OR rate was 46.2%. Responses were associated with DDR alts but not with age, gender, treatment, platinum-free interval or ML (table). In univariate logistic regression model, DDR status was associated with OR (p&lt;.001) while a trend was observed with ML as a continuous variable (p=.051). While DDR alts were associated with higher ML (all: p=.001, deleterious: p=.004), the effect of DDR alts on OR remained significant regardless of ML (&gt;median: p=.027; ≤median: p=.023), indicating that the effect of DDR was independent of ML. Conclusions: DDR alts appeared to be associated with OR to PD1/PDL1 blockade and should be integrated into future validation efforts along with other potential predictors of response. [Table: see text]